Jazz Pharmaceuticals (JAZZ) Resumen de Acciones
Jazz Pharmaceuticals plc identifica, desarrolla y comercializa productos farmacéuticos en Estados Unidos, Europa y a escala internacional. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 4/6 |
| Crecimiento futuro | 4/6 |
| Rendimiento pasado | 1/6 |
| Salud financiera | 3/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
JAZZ Community Fair Values
Create NarrativeSee what 51 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Jazz Pharmaceuticals plc
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$246.91 |
| Máximo en las últimas 52 semanas | US$250.49 |
| Mínimo de 52 semanas | US$105.00 |
| Beta | 0.32 |
| Cambio en 1 mes | 7.73% |
| Variación en 3 meses | 27.14% |
| Cambio de 1 año | 119.51% |
| Variación en 3 años | 94.79% |
| Variación en 5 años | 38.36% |
| Variación desde la OPV | 1,292.61% |
Noticias y actualizaciones recientes
Actualización de narrativa • Jun 23
JAZZ: HER2 GEA Priority Review Will Support Future Oncology Leadership Narrative
Analysts have lifted the central analyst price target for Jazz Pharmaceuticals stock from $225.53 to $257.00, pointing to stronger conviction in Ziihera's potential uptake in gastroesophageal adenocarcinoma and biliary tract cancer, a firmer outlook for the oncology portfolio, and perceived resilience of the Xywav franchise. Analyst Commentary Recent research on Jazz Pharmaceuticals highlights a clear split between bullish analysts focused on Ziihera driven growth and oncology expansion, and more cautious voices focused on neurology concentration risk and competitive pressure.Artículo de análisis • Jun 18
Jazz Pharmaceuticals (JAZZ) Stock Could Be 73% Below Fair Value After Recent Pullback
Jazz Pharmaceuticals stock reaction puts recent performance in focus With no single headline event driving Jazz Pharmaceuticals (JAZZ) today, the stock’s recent performance and fundamentals take center stage, inviting investors to reassess how its current pricing lines up with reported results. See our latest analysis for Jazz Pharmaceuticals. At a share price of $226.93, Jazz Pharmaceuticals has recently given back some of its shorter term gains, with a 7 day share price return that declined...
Actualización de narrativa • Jun 06
JAZZ: Oncology Readouts And CNS Durability Will Support Future Upside Potential
Analysts have lifted their fair value estimate for Jazz Pharmaceuticals to $304.19 from $263.59, citing higher modeled revenue growth, stronger profit margins supported by views on Ziihera and zanidatamab, and confidence in Xywav patent protections that they argue could justify a modestly lower future P/E multiple. Analyst Commentary Recent Street research on Jazz Pharmaceuticals presents a mixed but generally constructive tone, with several bullish analysts pointing to patent clarity on Xywav and the commercial opportunity for Ziihera and zanidatamab as key support pillars for their models.Recent updates
Actualización de narrativa • Jun 23
JAZZ: HER2 GEA Priority Review Will Support Future Oncology Leadership Narrative
Analysts have lifted the central analyst price target for Jazz Pharmaceuticals stock from $225.53 to $257.00, pointing to stronger conviction in Ziihera's potential uptake in gastroesophageal adenocarcinoma and biliary tract cancer, a firmer outlook for the oncology portfolio, and perceived resilience of the Xywav franchise. Analyst Commentary Recent research on Jazz Pharmaceuticals highlights a clear split between bullish analysts focused on Ziihera driven growth and oncology expansion, and more cautious voices focused on neurology concentration risk and competitive pressure.Artículo de análisis • Jun 18
Jazz Pharmaceuticals (JAZZ) Stock Could Be 73% Below Fair Value After Recent Pullback
Jazz Pharmaceuticals stock reaction puts recent performance in focus With no single headline event driving Jazz Pharmaceuticals (JAZZ) today, the stock’s recent performance and fundamentals take center stage, inviting investors to reassess how its current pricing lines up with reported results. See our latest analysis for Jazz Pharmaceuticals. At a share price of $226.93, Jazz Pharmaceuticals has recently given back some of its shorter term gains, with a 7 day share price return that declined...Actualización de narrativa • Jun 06
JAZZ: Oncology Readouts And CNS Durability Will Support Future Upside Potential
Analysts have lifted their fair value estimate for Jazz Pharmaceuticals to $304.19 from $263.59, citing higher modeled revenue growth, stronger profit margins supported by views on Ziihera and zanidatamab, and confidence in Xywav patent protections that they argue could justify a modestly lower future P/E multiple. Analyst Commentary Recent Street research on Jazz Pharmaceuticals presents a mixed but generally constructive tone, with several bullish analysts pointing to patent clarity on Xywav and the commercial opportunity for Ziihera and zanidatamab as key support pillars for their models.
Actualización de narrativa • May 23
JAZZ: Oncology Execution Risks Will Drive Future Multiple Compression Concerns
Analysts have lifted the fair value estimate for Jazz Pharmaceuticals from $188.00 to about $200.51, citing a higher assumed future P/E multiple. They link this to growing confidence in the broader Ziihera and zanidatamab opportunities, even as they factor in slightly lower long term profit margins and ongoing competitive pressure on legacy neurology drugs.Artículo de análisis • May 13
We Think You Can Look Beyond Jazz Pharmaceuticals' (NASDAQ:JAZZ) Lackluster Earnings
The market was pleased with the recent earnings report from Jazz Pharmaceuticals plc ( NASDAQ:JAZZ ), despite the...Artículo de análisis • May 08
Jazz Pharmaceuticals plc Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Jazz Pharmaceuticals plc ( NASDAQ:JAZZ ) investors will be delighted, with the company turning in some strong numbers...Actualización de narrativa • Apr 28
JAZZ: HER2 GEA Data Will Support Future Oncology Leadership Thesis
Analysts have nudged the price target on Jazz Pharmaceuticals higher to about $226, reflecting updated views on margins, central nervous system revenue durability, and upcoming oncology contributions following recent Q4 results and refreshed models. Analyst Commentary Recent Street research on Jazz Pharmaceuticals has centered on refreshed models following Q4 results, updated revenue guidance, and the expected contribution from oncology assets alongside the core central nervous system portfolio.Actualización de narrativa • Apr 13
JAZZ: CNS Cash Flows And Upcoming Oncology Launches Will Shape Execution Risks
Analysts have increased their average price target on Jazz Pharmaceuticals by $13 to $255, citing more supportive assumptions around revenue growth, profit margins and a slightly lower future P/E following the recent Q4 results and updated guidance. Analyst Commentary Recent research on Jazz Pharmaceuticals has largely centered on updated price targets and ratings following the company’s Q4 report and new guidance.Actualización de narrativa • Mar 30
JAZZ: CNS Cash Flows And HER2 Franchise Will Shape Oncology Execution Risks
Narrative Update on Jazz Pharmaceuticals Analysts have lifted price targets on Jazz Pharmaceuticals by roughly $10 to $45 into a $224 to $275 range, citing steady central nervous system demand, updated Ziihera and zanidatamab expectations following HERIZON-GEA data, and recent Q4 results that aligned with or modestly exceeded prior forecasts. Analyst Commentary Recent research on Jazz Pharmaceuticals has been broadly constructive, with several firms adjusting price targets higher after Q4 results and the HERIZON GEA data updates.Actualización de narrativa • Mar 16
JAZZ: HER2 Data And CNS Cash Flows Will Balance Oncology Execution Risks
The analyst price target for Jazz Pharmaceuticals has been adjusted slightly higher to reflect a $1 increase in fair value to $188, lower modeled revenue growth at 2.92%, a higher profit margin assumption at 21.90%, and a reduced future P/E of 13.95, as analysts point to a resilient central nervous system franchise, updated views on Ziihera and zanidatamab opportunities, and recent Q4 results and guidance. Analyst Commentary Recent research coverage points to generally constructive sentiment on Jazz Pharmaceuticals, with a cluster of higher price targets anchored to the company’s central nervous system portfolio and oncology pipeline, including Ziihera and zanidatamab.Actualización de narrativa • Mar 02
JAZZ: Oncology Readouts And CNS Durability Will Drive Future Upside Potential
Our analyst fair value estimate for Jazz Pharmaceuticals has moved from $230.00 to about $263.59, as analysts factor in stronger margin expectations, a slightly higher discount rate, and ongoing Street enthusiasm around Ziihera and the broader oncology pipeline following recent Q4 updates and HERIZON-GEA data presentations. Analyst Commentary Recent Street research has leaned constructive on Jazz Pharmaceuticals, with multiple bullish analysts revisiting their models following Q4 results and the latest HERIZON-GEA data.Seeking Alpha • Feb 26
Jazz Pharmaceuticals: Relief Rally On 2026 Oxybate Franchise's Outlook
Summary Jazz Pharmaceuticals is positioned for long-term value creation, with a relief rally following Q4 2025 results and 2026 outlook for the oxybate business. Jazz expects Xywav revenues to be flat or up mid-single digits in 2026, despite generic Xyrem headwinds, with the oxybate franchise revenues projected at $1.8-1.9 billion. Strong Modeyso launch and robust Ziihera phase 3 data in first-line GEA set up new growth drivers, with Ziihera's U.S. launch anticipated in 2H 2026. Multiple expansion and valuation re-rating are possible as investors look past widespread availability of Xyrem generics, with Ziihera and other assets supporting (at least) mid-single-digit revenue growth. Read the full article on Seeking AlphaActualización de narrativa • Feb 16
JAZZ: HER2 Practice-Changing GEA Data Will Drive Future Oncology Leadership
Narrative Update Overview The analyst price target for Jazz Pharmaceuticals has moved higher, with our fair value estimate rising from $213 to $219.40 as analysts factor in stronger Ziihera and zanidatamab potential, supported by recent HERIZON-GEA data and updated Street research. Analyst Commentary Recent Street research on Jazz Pharmaceuticals has been largely constructive, with multiple firms updating their work after the detailed HERIZON-GEA-01 readout and related discussions around Ziihera and zanidatamab.Actualización de narrativa • Feb 02
JAZZ: Practice-Changing HER2 Data Will Drive Oncology Upside And Rebalance Legacy Risks
Analysts have raised their price targets on Jazz Pharmaceuticals by approximately $10 to $30 per share, citing what they describe as practice-changing HERIZON GEA data for Ziihera and a clearer oncology pipeline driver as key supports for the higher valuations. Analyst Commentary Across recent research notes, analysts have been revising their views on Jazz Pharmaceuticals primarily around the HERIZON GEA data for Ziihera and what it could mean for the oncology portfolio.Actualización de narrativa • Jan 19
JAZZ: Practice-Changing HER2 Data Will Rebalance Oncology Potential And Legacy Risks
Jazz Pharmaceuticals' updated analyst price target has edged down by US$1 to US$187 as analysts factor in slightly higher growth and margin assumptions, supported by recent HERIZON-GEA-01 data that they describe as practice changing for Ziihera and potentially supportive of new standard-of-care use across several HER2+ cancer settings. Analyst Commentary Across recent research, most firms are reacting to the HERIZON-GEA-01 data by lifting their Jazz Pharmaceuticals price targets and highlighting Ziihera and zanidatamab as key value drivers.Actualización de narrativa • Jan 05
JAZZ: Oncology Data Will Reshape Revenue Mix While Legacy Headwinds Persist
We are raising our Jazz Pharmaceuticals fair value estimate to $188 from $147 as analysts boost price targets following positive HERIZON-GEA-01 data for Ziihera, which they see as a potential new standard of care and a multibillion dollar revenue driver. Analyst Commentary Street research following the HERIZON-GEA-01 topline readout has turned broadly constructive on Jazz Pharmaceuticals, with multiple firms lifting price targets and reiterating positive ratings.Actualización de narrativa • Dec 18
JAZZ: HER2-Positive GEA Breakthrough Will Drive Future Oncology Leadership
Analysts have nudged their fair value estimate for Jazz Pharmaceuticals higher to $213.00 from $208.50, reflecting stronger long term revenue growth expectations and a richer future P/E multiple, supported by increasingly bullish views on Ziihera's potential to become a new standard of care in HER2 positive GEA and a key oncology growth driver. Analyst Commentary Bullish analysts are largely focused on the upside from Ziihera's HERIZON-GEA-01 data, with multiple research shops lifting price targets and embedding higher long term oncology growth into their models.Actualización de narrativa • Dec 04
JAZZ: HER2-Positive GEA Success Will Drive Future Oncology Leadership And Upside
Our fair value estimate for Jazz Pharmaceuticals has nudged higher to $208.50 from $206.38, reflecting analysts' upward revisions to price targets as they factor in expectations of stronger long term revenue growth and profitability. This is driven by Ziihera's potential as a new standard of care in HER2 positive GEA and broader oncology indications.Actualización de narrativa • Nov 20
JAZZ: Recent Positive Trial Data Will Drive Future Leadership In HER2-Positive Oncology
Analysts have increased their price target for Jazz Pharmaceuticals from approximately $186 to $206 per share. They cite improved revenue growth projections and recent strong clinical data supporting the potential of Ziihera as a standard-of-care therapy in HER2-positive cancers.Artículo de análisis • Nov 18
Improved Revenues Required Before Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock's 25% Jump Looks Justified
Despite an already strong run, Jazz Pharmaceuticals plc ( NASDAQ:JAZZ ) shares have been powering on, with a gain of...Actualización de narrativa • Aug 30
Emerging Therapies And Portfolio Expansion Will Shape Future Markets
Analysts have modestly raised their price targets for Jazz Pharmaceuticals, driven by growing confidence in Modeyso's commercial prospects and expanded market potential, partially offset by persistent challenges in other segments, resulting in a new consensus target of $186.47. Analyst Commentary Bullish analysts are increasingly positive on the commercial potential of Modeyso following its recent approval, citing higher-than-expected pricing, a dedicated launch strategy, and strong patient/prescriber interest.Artículo de análisis • Aug 09
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Last week, you might have seen that Jazz Pharmaceuticals plc ( NASDAQ:JAZZ ) released its second-quarter result to the...Artículo de análisis • Jul 21
Lacklustre Performance Is Driving Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Low P/E
With a price-to-earnings (or "P/E") ratio of 14.2x Jazz Pharmaceuticals plc ( NASDAQ:JAZZ ) may be sending bullish...Rentabilidad de los accionistas
| JAZZ | US Pharmaceuticals | Mercado US | |
|---|---|---|---|
| 7D | 1.4% | -0.5% | 0.6% |
| 1Y | 119.5% | 45.8% | 19.5% |
Rentabilidad vs. Industria: JAZZ superó a la industria US Pharmaceuticals, que obtuvo un rendimiento del 45.8% el año pasado.
Rentabilidad vs. Mercado: JAZZ superó al mercado US, que obtuvo un rendimiento del 19.5% el año pasado.
Volatilidad de los precios
| JAZZ volatility | |
|---|---|
| JAZZ Average Weekly Movement | 4.3% |
| Pharmaceuticals Industry Average Movement | 9.2% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Precio estable de las acciones: JAZZ no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de JAZZ (4%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2003 | 2,890 | Renee Gala | www.jazzpharma.com |
Jazz Pharmaceuticals plc identifica, desarrolla y comercializa productos farmacéuticos en Estados Unidos, Europa y a nivel internacional. La empresa ofrece Xywav para el tratamiento de la cataplejía o la somnolencia diurna excesiva (SDE) asociada a la narcolepsia y la hipersomnia idiopática (HI); Epidiolex para las crisis epilépticas asociadas al síndrome de Lennox-Gastaut (LGS), al síndrome de Dravet (DS) o al complejo de esclerosis tuberosa (TSC); Rylaze para el tratamiento de la leucemia linfoblástica aguda o el linfoma linfoblástico; Enrylaze para tratar la leucemia linfoblástica aguda y el linfoma linfoblástico; Zepzelca para el tratamiento del cáncer de pulmón de células pequeñas metastásico con progresión de la enfermedad durante o tras una quimioterapia basada en platino; Ziihera para el tratamiento de los cánceres de las vías biliares HER2-positivos; Modeyso para el tratamiento del glioma difuso de la línea media que presenta una mutación H3 K27M; y Defitelio para el tratamiento de la enfermedad venooclusiva grave. También está desarrollando Zanidatamab, en ensayo de fase III, para el tratamiento del adenocarcinoma gastroesofágico (GEA) HER2-positivo y de los cánceres de las vías biliares (BTC); Dordaviprone para el tratamiento del glioma difuso con mutación H3 K27M; y Vyxeos para el tratamiento de la leucemia mieloide aguda de nuevo diagnóstico relacionada con el tratamiento.
Resumen de fundamentos de Jazz Pharmaceuticals plc
| Estadísticas fundamentales de JAZZ | |
|---|---|
| Capitalización bursátil | US$15.59b |
| Beneficios(TTM) | US$29.45m |
| Ingresos (TTM) | US$4.44b |
526.6x
Ratio precio-beneficio (PE)3.5x
Ratio precio-ventas (PS)¿Está JAZZ sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de JAZZ | |
|---|---|
| Ingresos | US$4.44b |
| Coste de los ingresos | US$377.25m |
| Beneficio bruto | US$4.06b |
| Otros gastos | US$4.03b |
| Beneficios | US$29.45m |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 0.47 |
| Margen bruto | 91.50% |
| Margen de beneficio neto | 0.66% |
| Ratio deuda/patrimonio | 118.1% |
¿Cómo se ha desempeñado JAZZ a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/07/09 12:25 |
| Precio de las acciones al final del día | 2026/07/09 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también contamos con guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Jazz Pharmaceuticals plc está cubierta por 48 analistas. 18 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Brian Skorney | Baird |
| Joel Beatty | Baird |
| null null | Baird |